The tumor regression grade (TRG) role was investigated by multiple correspondence analysis (MCA) in 174 low rectal cancer patients undergone neoadjuvant chemoradiation and radical surgery, with a minimum follow-up of 10 years. The TRG 1 and 2 showed better survival than TRG 4 and 5 subgroups. MCA allocated TRG 3 together with other prognostic variables better than multivariate analysis. Background: The role of Mandard's tumor regression grade (TRG) classification is still controversial in defining the prognostic role of patients who have undergone neoadjuvant chemoradiation (CRT) and total mesorectal excision. The present study evaluated multiple correspondence analysis (MCA) as a tool to better cluster variables, including TRG, for a homogeneous prognosis. Patients and Methods: A total of 174 patients with a minimum follow-up period of 10 years were stratified into 2 groups: group A (TRG 1-3) and group B (TRG 4-5) using Mandard's classification. Overall survival and disease-free survival were analyzed using univariate and multivariate analysis. Subsequently, MCA was used to analyze TRG plus the other prognostic variables. Results: The overall response to CRT was 55.7%, including 13.2% with a pathologic complete response. TRG group A correlated strictly with pN status (P ¼ .0001) and had better overall and disease-free survival than group B (85.1% and 75.6% vs. 71.1% and 67.3%; P ¼ .06 and P ¼ .04, respectively). The TRG 3 subset (about one third of our series) showed prognostically heterogeneous behavior. In addition to multivariate analysis, MCA separated TRG 1 and TRG 2 versus TRG 4 and TRG 5 well and also allocated TRG 3 patients close to the unfavorable prognostic variables. Conclusion: TRG classification should be used in all pathologic reports after neoadjuvant CRT and radical surgery to enrich the prognostic profile of patients with an intermediate risk of relapse and to identify patients eligible for more conservative treatment. Thus, MCA could provide added value.
Introduction
The combination of neoadjuvant chemoradiation (CRT) and radical surgery, including total mesorectal excision (TME), significantly improved the curability of pathologic stage II and III rectal cancer. 1, 2 In particular, recent randomized phase III trials have demonstrated that the addition of chemotherapy to longterm preoperative radiotherapy (RT) significantly enhanced local control, disease-free survival (DFS), and overall survival (OS) in patients with locally advanced resectable low rectal cancer.
Favorable outcomes were observed above all in patients responding to neoadjuvant CRT, [6] [7] [8] with a response rate of 30% to 80% and 8% to 44% achieving a complete response (CR). 9, 10 Nevertheless, it is still difficult to know how to identify the responders and their oncologic outcomes, because reliable predictive factors of response have not yet been recognized. It is well known that a discrepancy exists between the clinical and pathologic responses. Preoperative clinical repeat staging using endorectal ultrasonography (ERUS), computed tomography (CT), and magnetic resonance imaging (MRI) risks overestimating the amount of downstaging compared with the pathologic examination. 7 Moreover, residual cancer microfoci in critical areas (mesorectal fat, regional lymph nodes) can enhance the risk of a discrepancy between the clinical and pathologic responses. In 1994, Mandard et al 11 proposed a new classification system using the tumor regression grade (TRG) to evaluate histologic tumor regression after CRT in esophageal squamous cancer. Five different groups were identified: TRG 1, the absence of residual cancer; TRG 2, the presence of residual cancer cells scattered throughout the fibrosis; TRG 3, an increase in the number of residual cancer cells but fibrosis still predominant; TRG 4, residual cancer outgrowing fibrosis; and TRG 5, the absence of regressive changes. 11 Subsequently, other classifications with similar objectives were proposed. [12] [13] [14] [15] [16] [17] At present, the TRG classification can be used to assess the response to CRT, detecting histologic changes after neoadjuvant CRT.
The aims of our prospective study were to evaluate the role of the TRG for rectal cancer patients who had undergone radical resection by TME after CRT, the relationship of the TRG with the pathologic response using the TNM staging system, and the risk of local and distant relapse.
With a minimum follow-up period of 10 years, the prognostic correlations of the TRG in terms of OS and DFS were analyzed, and the role of multiple correspondence analysis (MCA) was investigated to observe the distribution of the prognostic variables and to identify more homogeneous patient subgroups.
Patients and Methods

Patient Characteristics and Diagnostic Evaluation
At the surgery department of the "Regina Elena" National Cancer Institute of Rome, a consecutive series of 174 patients with extraperitoneal clinical (c)T3-T4 or T2NþM0 rectal cancer underwent long-term neoadjuvant CRT, followed by radical TME, from January 1999 to January 2006. The male/female ratio and median age was 1.6 and 63 years, respectively.
In all 174 patients, adenocarcinoma had been diagnosed by biopsies taken during colonoscopy. Before and after CRT, the clinical stage was defined from multislice triphasic CT, pelvic MRI, and ERUS scans. The median tumor distance from the anal verge was 5 cm (range, 2.5-10 cm).
Treatment and Pathologic Stage
Preoperative, pelvic long-term RT to 5040 cGy was delivered in 28 daily fractions of 180 cGy, together with concomitant, radiationintensifying fluorouracil-based systemic chemotherapy regimens. The interval from the end of neoadjuvant CRT to surgery was 45 to 60 days. A few days before surgery, the disease for all the patients was clinically restaged. A sphincter-saving surgical procedure (nervesparing, TME anterior resection with colorectal or coloanal anastomosis) was performed in 155 patients (89.1%), and negative clearance from the tumor distal margin was always confirmed histologically. The remaining 19 patients (10.9%) underwent TME abdominal perineal resection.
All the surgical specimens were analyzed by the same pathologist and classified using both the pathologic TNM stage and the Mandard system. After histopathologic diagnosis and compared with the clinical stage before CRT and surgery, the response of all 174 patients was defined as follows: CR, no pathologic tumor (T0) or only microscopic residual cancer foci were detected (pT0-TmicN0); partial response, pathologic downstaging was observed (pT1-T2N0); stable disease, no downstaging or local or locoregional progression was observed (pT3, same N); progression, local (T4 from T3) or locoregional (Nþ from NÀ) tumor spread had occurred. Lymph nodes were considered downstaged when no residual cancer cells were found in patients with clinically staged Nþ disease (diameter > 1 cm) before CRT. Of the 174 patients, 23 (13.2%), 74 (42.5%), 30 (17.3%), 30 (17.3%), and 17 (9.7%) were classified as having pT0N0M0, stage I, stage II, stage III, and stage IV, respectively. In the 17 stage IV patients (all with pT3-T4), single, small liver metastases or metastatic extraregional lymph nodes (not detected during preoperative staging) were found intraoperatively and removed, together with the primary rectal tumor. The Mandard TRG 1, 2, and 3 subgroups were included in group A and the TRG 4 and 5 subgroups in group B.
Adjuvant systemic chemotherapy was administered to only 28.7% of the patients (all with pathologic stage III-IV). All clinical and pathological characteristics for the present series are summarized in Table 1 .
Follow-up Protocol
Each patient underwent a physical examination every 3 months in the first postoperative year and every 6 months thereafter. Colonoscopy, ERUS, CT, MRI, and serum marker (carcinoembryonic antigen and cancer antigen 19.9) measurements were used to detect relapses and were scheduled according to the different pathologic stages. The minimum follow-up period was 10 years. In the case of metachronous resectable liver or lung metastases or anastomotic recurrence, surgery was performed. When pelvic recurrence developed ! 2 years after resection of the primary tumor, repeat irradiation with concomitant chemotherapy was delivered, with surgery performed afterward, when possible. Multiple distant metastases were treated by systemic chemotherapy when unresectable and by surgery when resectable.
Statistical Analysis
The correlations among the variables were tested using Pearson's exact c 2 test. The OS and DFS curves were estimated using the Kaplan-Meier product-limit method. The log-rank test was used to assess for differences among the subgroups. Significance was defined at the P < .05 level.
The hazard ratio and 95% confidence intervals were estimated for each variable using the Cox univariate model and adopting the most suitable prognostic category as the referent group. A multivariate Cox proportional model was also developed using stepwise regression (forward selection) with predictive variables significant on univariate analysis. The enter and removal limit was P ¼ .10 and e14 -Clinical Colorectal Cancer March 2018 TRG After Neoadjuvant CRT and TME for Low Rectal Cancer P ¼ .15, respectively. The SPSS program, version 11.0, was used for statistical analysis.
Finally, MCA was performed as a descriptive and exploratory technique designed to analyze simple 2-way and multiple-way tables. MCA was used to evaluate the possible relationships among all the variables and to identify specific profiles. Associations between features are represented graphically in MCA, providing a graphic representation of the statistical relationships among distinct features, with the position of each exclusively informative. 18, 19 This representation aims to visualize the similarities and/or differences in the profiles simultaneously, identifying those dimensions that contain most of the data variability. The position of the points in the MCA graph is also informative. Categories that plot close to each other will be significantly related statistically and have patterns of relative frequencies. This association is also valuable statistically when the points are located far from the origin of the graph and represents a mean, uninformative profile.
18,19
Results
TRG Correlations and Outcomes
A pathologic response according to the T stage was observed in 97 patients (55.7%). Of these patients, 23 (13.2%) had a CR. The TRG distribution was as follows: TRG 1, 25 patients (14.4%); TRG 2, 37 (21.3%); TRG 3, 59 (33.9%); TRG 4, 26 (14.9%); and TRG 5, 27 patients (15.5%). A statistically significant (P ¼ .01) correlation between TRG group A and the pT0-T2 subgroup was observed but not with group B.
When the CR patients were analyzed alone, a greater proportion were in group A (P ¼ .003; Table 2 ). The only patient with a pCR in group B had multiple microscopic cancer foci classified as TRG 4. Also, a high correlation with pN status was observed in group A (P ¼ .0001). The TRG 3 subgroup included most of the patients with pT3-T4 and N0 (44.0% and 36.6%, respectively), with different correlations with the pT and pN stage compared with the TRG 1 and TRG 2 subgroups (Table 3) .
Survival
After a minimum follow-up period of 10 years, local and/or distant relapse was detected in 41 cases (23.5%), of which 13 (7.4%) were pelvic. No significant correlation was found between the TRG distribution and the incidence or location of relapse. Also, the great majority of the TRG 3 patients (82%) had no relapse (Table 4) .
The crude 5-year OS and DFS rates for the present series were 79.3% and 70.6%, respectively. The OS and DFS for group A was better (85.1% and 75.6%, respectively) than that of group B (71.1% and 67.3%; P ¼ .06 and P ¼ .04, respectively; Figure 1 ). Analyzing the data for the TRG 3 patients alone, their OS was closer to that of the TRG 1 and 2 patients (group A) than that of the TRG 4 and 5 patients (group B; P ¼ .05; Figure 2 ). On multivariate analysis, the only statistically significant prognostic factor was the pN stage for both OS (P ¼ .0007) and DFS (P ¼ .02).
In addition to revealing the absence of a correlation between the TRG and relapse, MCA demonstrated how the distribution of different clinical and pathologic parameters clustered factors of the 
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Clinical Colorectal Cancer March 2018 -e15 same prognostic value. The correlation among those different parameters was been determined by their distribution in the 4 quadrants. Some favorable variables were located together with no relapse in the 2 right quadrants of the MCA graph: TRG group A, pNÀ status and being alive. For TRG group B, pNþ status and cancer-related deaths were found in the 2 left quadrants of the MCA graph, together with local and/or distant relapse. The 2 couples of quadrants enclose the opposite extremities of the series: the most favorable parameters in the right quadrants and those most unfavorable in the left quadrants. Moreover, the MCA graph showed the borderline location of TRG 3 near the crossing point of the axes (Figure 3 ).
Discussion
In the present series, the pathologic response rate to neoadjuvant CRT overlapped with the rates previously reported. 9, 10 Usually, the TRG 1 and 2 subgroups will have an extremely favorable prognosis, even if residual cancer cell spots (TRG 2) are sometimes observed in the perirectal fat (stage pT3). In our study the TRG 1 and 2 and TRG 4 and 5 subgroups each represented about one third of all patients, with the TRG 3 group, the last one third.
When TRG 3 was evaluated alone, the Kaplan-Meier curve showed significantly better OS compared with that for TRG 4 and 5. After neoadjuvant CRT, our TRG 3 subgroup showed a great chance of achieving cure with radical surgery; therefore, one might suggest avoiding adjuvant chemotherapy for node-negative TRG 3 patients.
MCA confirmed the favorable role of TRG 1 and 2. Above all, as shown in Figure 3 , the MCA graph showed the clustering of the favorable prognostic variables on the same side (pT0, TRG 1-2, pNÀ, no relapse, sphincter-saving surgery, alive status), with the unfavorable variables (TRG 4-5, local and distant relapse, cancer death, abdominal perineal resection) on the opposite side. The potentially favorable profile of TRG 3 was enhanced by MCA, because its position could be clearly visualized near the crossing point of the axes, separated and far from the TRG 4 and 5 subgroups. This result differs from most of the previously published data.
In previous reports, a wide discordance regarding the prognostic role of TRG emerged. Dhadda et al 20 found the TRGs 1 and 2 were associated with better survival. However, the multivariate Cox model did not include it among the significant prognostic factors. 20 Much more favorable results for TRG 1 and 2 patients were reported by TRG After Neoadjuvant CRT and TME for Low Rectal Cancer
Vecchio et al. 21 Their univariate analysis showed a correlation between TRGs 1 and 2 and a low risk of local recurrence, metastasis-free survival, DFS, and OS. 21 The multivariate analysis confirmed the TRG was predictive of DFS and pathologic nodal involvement. 21 Another multivariate analysis showed that the TRG correlated more significantly than did downstaging. 22 Other studies demonstrated the value of TRG 3 as an effective predictor of poorer DFS. [20] [21] [22] In contrast, the results from Rodel et al 17 failed to show any prognostic role for TRG on multivariate analysis for either OS or DFS. Considering other TRG classifications, a discrepancy in the results was confirmed. When the Dworak system was used, its intermediate grade 2 subset was considered prognostically favorable. 12 On univariate analysis, Kim et al 23 
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Clinical Colorectal Cancer March 2018 -e17 28 In an original contribution by Chetty et al, 29 17 gastrointestinal pathologists evaluated the agreement rate for the 3 scoring systems (Mandard, Dworak, and the 3-class modified system) and found poor concordance. The discordance was attributed to the lack of clarity in the criteria for classification and their interpretation. 29 Recently, Memorial Sloan Kettering
Cancer Center compared the predictive accuracies of the different classifications of rectal cancer regression proposed in the published data and concluded that the American Joint Committee on Cancer staging system demonstrated the most accuracy. 30 A macroscopic discrepancy among all these cited classifications of rectal tumor regression has clearly emerged. Probably, the discrepancy has resulted from differences in the subjective quantitative evaluation of residual disease by several pathologists, especially for patients with a partial response, which represented at least one third of the cases in each series. In particular, the presence of fibrosis and residual cancer cells (TRG 3) caused difficulty in the homogeneous classification and disagreement among pathologists.
Because TRG alone was not a prognostic independent variable in all the multivariate analyses, we thought include MCA for added value. MCA could represent a method to identify those TRG 3 patients with a very low risk of relapse, which could then allow them to avoid adjuvant therapy and an aggressive follow-up protocol. In addition, the unfavorable MCA quadrants identified high-risk patients who require adjuvant treatment and a strict follow-up protocol to allow for the detection of early disease relapse. The use of MCA could lead to modulation of the follow-up protocol for rectal cancer patients who have undergone neoadjuvant CRT and radical surgery, with a potential benefit in cost-effectiveness.
Conclusion
The TRG classification should be included in all pathologic reports after neoadjuvant CRT and radical surgery for locally advanced rectal cancer to better specify the weight of a favorable prognostic profile and to not overtreat those with an intermediate risk of relapse (TRG 3) with adjuvant chemotherapy. In the most favorable subgroups, use of the MCA represents an added value, allowing for a stronger indication for organ-conserving surgery for Mandard TRG 1 and 2 patients.
Clinical Practice Points
For patients who have undergone neoadjuvant CRT for rectal cancer, the TRG can be evaluated using 5 different classification systems. Some studies showed a correlation between the TRG and prognosis but others did not. The interobserver variability among pathologists and differences in patients with an incomplete response are critical points. In each series, patients with partial regression represented the majority, and their prognosis was heterogeneous. In our series of 174 low rectal cancer patients who had undergone TME after neoadjuvant CRT, we classified tumor regression using the Mandard system and evaluated its relationship with recurrent disease, TNM, OS, and DFS. Moreover, we used MCA to identify the distribution of clinicopathologic variables and to cluster homogeneous subgroups of patients by prognosis. MCA allocated the patients to 4 quadrants, clustering them with all other favorable versus unfavorable variables. In particular, TRG 3 patients were well separated from the both TRG 1 and 2 and TRG 4 and 5 subsets. In the future, in well-selected subsets, MCA could represent a further discriminant for choosing the best multimodality treatment, both surgically (TME vs. local) and adjuvantly, avoiding the "supercure" of patients with a low risk of recurrence and indicating a more aggressive follow-up protocol for high-risk patients.
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